10.90

5.71% -0.66

After Hours: 10.98 0.08 +0.73%

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $10.90, with a volume of 2.83M. It is down -5.71% in the last 24 hours and down -32.55% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Previous Close:

$11.56

Open:

$11.61

24h Volume:

2.83M

Relative Volume:

1.31

Market Cap:

$1.33B

Revenue:

$631.73M

Net Income/Loss:

$-239.78M

P/E Ratio:

-5.396

EPS:

-2.02

Net Cash Flow:

$-33.45M

1W Performance:

-11.49%

1M Performance:

-32.55%

6M Performance:

-52.63%

1Y Performance:

-76.61%

1-Day Range:

$10.83

$11.85

1-Week Range:

$10.83

$13.12

52-Week Range:

$10.80

$48.42

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1169)

Industry

Health Information Services (58)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,306

Twitter

@10xgenomics

Next Earnings Date

2024-10-31

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	10.90	1.33B	631.73M	-239.78M	-33.45M	-2.02
VEEV Veeva Systems Inc	225.79	36.66B	2.66B	665.91M	1.08B	4.05
DOCS Doximity Inc	72.37	13.58B	516.85M	174.11M	217.38M	0.87
SOLV Solventum Corp	73.02	12.61B	8.26B	66.00M	1.17B	0.3682
TEM Tempus Ai Inc	68.09	10.72B	640.44M	-743.28M	-206.93M	-11.29
HQY Healthequity Inc	108.60	9.41B	1.15B	96.70M	-161.99M	1.09

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

03:00 AM

Harvard, 10x Genomics Settle Patent Dispute With Vizgen - Harvard Crimson

03:00 AM

Feb 21, 2025

10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St

Feb 21, 2025

Alberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 21, 2025

Feb 19, 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - Eastern Progress

Feb 19, 2025

Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat

Feb 19, 2025

Feb 18, 2025

10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat

Feb 18, 2025

10x Genomics (NASDAQ:TXG) Shares Up 8.3%Still a Buy? - MarketBeat

Feb 18, 2025

Feb 17, 2025

Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 17, 2025

10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat

Feb 17, 2025

10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com

Feb 17, 2025

10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat

Feb 17, 2025

Leerink Partners Downgrades 10x Genomics (NASDAQ:TXG) to Market Perform - MarketBeat

Feb 17, 2025

Feb 16, 2025

10x Genomics (NASDAQ:TXG) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat

Feb 16, 2025

Entropy Technologies LP Purchases 27,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 16, 2025

Feb 15, 2025

10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan Stanley - MarketBeat

Feb 15, 2025

Leerink Partnrs Forecasts 10x Genomics Q1 Earnings - MarketBeat

Feb 15, 2025

Barclays Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 15, 2025

Feb 14, 2025

Canaccord Genuity Group Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 14, 2025

UBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $14.00 - MarketBeat

Feb 14, 2025

10x Genomics falls on quarterly EPS miss, 2025 revenue guidance concern - MSN

Feb 14, 2025

Morgan Stanley Trims Price Target on 10x Genomics to $26 From $28, Keeps Overweight Rating - Marketscreener.com

Feb 14, 2025

10x Genomics Inc Reports Q4 Revenue of $165M, Beating Estimates; EPS of -$0.40 Misses Expectations - GuruFocus.com

Feb 14, 2025

Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 14, 2025

Feb 13, 2025

10X Genomics Earnings Call: Innovations Amidst Revenue Challenges - TipRanks

Feb 13, 2025

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Victoria Advocate

Feb 13, 2025

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - Benzinga

Feb 13, 2025

10X Genomics stock plunges to 52-week low of $11.89 - MSN

Feb 13, 2025

10x Genomics, Inc. Provides Earnings Guidance for the Year 2025 -February 12, 2025 at 04:05 pm EST - Marketscreener.com

Feb 13, 2025

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN

Feb 13, 2025

UBS Adjusts Price Target on 10x Genomics to $14 From $20, Keeps Neutral Rating -February 13, 2025 at 10:09 am EST - Marketscreener.com

Feb 13, 2025

10x Genomics (NASDAQ:TXG) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat

Feb 13, 2025

10x Genomics Shares Tumble on Fear Over Cuts to NIH - Barron's

Feb 13, 2025

Leerink Partners Downgrades 10x Genomics to Market Perform From Outperform, Adjusts Price Target to $12 From $25 - Marketscreener.com

Feb 13, 2025

10x Genomics, Inc. SEC 10-K Report - TradingView

Feb 13, 2025

10x Genomics revenue increases 10% to USD 165M in Q4 2024 - Medical Buyer

Feb 13, 2025